

Elisabetta Munzone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8794622/publications.pdf>

Version: 2024-02-01

124
papers

5,112
citations

147566

31
h-index

91712

69
g-index

127
all docs

127
docs citations

127
times ranked

6715
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
2	Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. <i>Journal of Clinical Oncology</i> , 1995, 13, 2688-2699.	0.8	515
3	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
4	Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5693-5699.	0.8	235
5	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	1.3	212
6	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
7	Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. <i>Annals of Oncology</i> , 2008, 19, 891-897.	0.6	144
8	Paclitaxel in Metastatic Breast Cancer: a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With Anthracyclines. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1169-1175.	3.0	136
9	Therapeutic effect of β -blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 567-575.	1.1	113
10	Pharmacokinetics of anticancer agents in patients with impaired liver function. <i>European Journal of Cancer</i> , 1998, 34, 33-46.	1.3	110
11	Clinical overview of metronomic chemotherapy in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 631-644.	12.5	109
12	Should liver metastases of breast cancer be biopsied to improve treatment choice?. <i>Annals of Oncology</i> , 2011, 22, 2227-2233.	0.6	103
13	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	1.1	100
14	Changes of <i>HER2</i> Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 392-397.	1.1	96
15	Optic Nerve Disturbances: a New Form of Paclitaxel Neurotoxicity. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1099-1101.	3.0	89
16	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006, 17, 750-762.	0.6	76
17	A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. <i>British Journal of Cancer</i> , 2009, 100, 28-36.	2.9	76
18	Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 211-217.	1.1	70

#	ARTICLE	IF	CITATIONS
19	Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. <i>Breast Cancer Research</i> , 2005, 8, R4.	2.2	67
20	Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2016, 139, 212-219.	2.3	63
21	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282.	1.1	61
22	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF- β 2) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	1.1	59
23	Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. <i>Acta Oncologica</i> , 2013, 52, 1649-1656.	0.8	56
24	Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 340-346.	1.1	46
25	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 701-708.	3.3	45
26	Metronomic therapy and breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 942-950.	3.4	44
27	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. <i>Future Oncology</i> , 2016, 12, 373-387.	1.1	43
28	Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2006, 17, 322-329.	0.6	40
29	Synergistic Activity of Oxaliplatin and 5-Fluorouracil in Patients With Metastatic Colorectal Cancer With Progressive Disease While on or After 5-Fluorouracil. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 279-283.	0.6	39
30	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?. <i>Annals of Oncology</i> , 1998, 9, 917-919.	0.6	35
31	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. <i>Cancer Letters</i> , 2017, 400, 276-281.	3.2	34
32	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
33	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	1.1	32
34	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. <i>Breast Care</i> , 2018, 13, 177-181.	0.8	31
35	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
36	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 6, 518-524.	1.1	25
38	Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. <i>Breast</i> , 2010, 19, 33-37.	0.9	25
39	Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474.	0.4	25
40	Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. <i>Annals of Oncology</i> , 2017, 28, 305-312.	0.6	25
41	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. <i>British Journal of Cancer</i> , 2019, 121, 325-331.	2.9	25
42	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 239-245.	0.6	23
43	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997.	1.0	23
44	CMF revisited in the 21st century. <i>Annals of Oncology</i> , 2012, 23, 305-311.	0.6	22
45	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
46	Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999, 10, 993-996.	0.6	20
47	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. <i>Advances in Therapy</i> , 2019, 36, 381-406.	1.3	19
48	Development and psychometric testing of a breast cancer patient-profiling questionnaire. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 133.	1.0	18
49	Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 95-100.	0.6	17
50	Prognostic value of circulating tumor cells in primary and metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 203-214.	1.1	16
51	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	0.8	16
52	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2 ⁺ metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials. <i>ESMO Open</i> , 2021, 6, 100332.	2.0	16
53	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	0.4	15
54	<p>Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 45-56.	1.0	15

#	ARTICLE	IF	CITATIONS
55	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. <i>Nature Communications</i> , 2022, 13, 2642.	5.8	15
56	Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. <i>Breast</i> , 2005, 14, 380-383.	0.9	14
57	Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. <i>Annals of Oncology</i> , 2007, 18, 1969-1975.	0.6	14
58	Surgical Resection Margins after Breast-Conserving Surgery: Senonetwork Recommendations. <i>Tumori</i> , 2016, 102, 284-289.	0.6	14
59	Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. <i>Cancer Letters</i> , 2017, 400, 259-266.	3.2	14
60	Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. <i>Clinical Breast Cancer</i> , 2015, 15, e237-e241.	1.1	13
61	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 328-335.	1.1	13
62	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	1.7	13
63	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877743.	1.4	12
64	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2051-2061.	0.8	11
65	Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. <i>Anticancer Research</i> , 2014, 34, 6677-83.	0.5	11
66	Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. <i>Journal of Neuro-Oncology</i> , 1995, 25, 221-225.	1.4	10
67	Mutations targeting the coagulation pathway are enriched in brain metastases. <i>Scientific Reports</i> , 2017, 7, 6573.	1.6	10
68	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	1.1	9
69	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020, 53, 138-142.	0.9	9
70	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 426.	0.6	8
71	Unexpected Right Phrenic Nerve Injury During 5-Fluorouracil Continuous Infusion Plus Cisplatin and Vinorelbine in Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2000, 92, 755-755.	3.0	8
72	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. <i>Annals of Oncology</i> , 2015, 26, 2442-2449.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients.. Journal of Clinical Oncology, 2013, 31, 1061-1061.	0.8	8
74	Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Seminars in Oncology, 1994, 21, 29-33.	0.8	8
75	1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. European Journal of Cancer, 2015, 51, S291-S292.	1.3	7
76	Reply to Comments on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines." British Journal of Cancer, 2019, 121, 806-806.	2.9	7
77	Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?. Anti-Cancer Drugs, 2012, 23, 1089-1098.	0.7	6
78	Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. Breast Cancer Research and Treatment, 2013, 138, 303-310.	1.1	6
79	Picking the optimal endocrine adjuvant treatment for pre-menopausal women. Breast, 2015, 24, S11-S14.	0.9	6
80	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology, 2016, 12, 2001-2008.	1.1	6
81	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC Cancer, 2019, 19, 902.	1.1	6
82	A phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. Journal of Clinical Oncology, 2007, 25, 8579-8579.	0.8	6
83	Predicting Effective Adaptation to Breast Cancer to Help Women BOUNCE Back: Protocol for a Multicenter Clinical Pilot Study. JMIR Research Protocols, 2022, 11, e34564.	0.5	6
84	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 703-714.	0.9	5
85	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Drugs, 2015, 75, 1311-1321.	4.9	5
86	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Research and Treatment, 2018, 170, 351-360.	1.1	5
87	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
88	Ten-year outcome results of cT4 breast cancer after neoadjuvant treatment. Journal of Surgical Oncology, 2021, 124, 1242-1250.	0.8	5
89	Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen). Annals of Oncology, 1999, 10, 1394-1395.	0.6	4
90	Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Annals of Oncology, 2005, 16, 1609-1617.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013, 22, S161-S164.	0.9	4
92	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. <i>Breast</i> , 2019, 48, S49-S52.	0.9	4
93	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	0.7	4
94	Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 11017-11017.	0.8	4
95	Oral vinorelbine in combination with capecitabine: phase I study in patients with metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 134.	2.2	3
96	Targeting the subtypes of breast cancer: rethinking investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 191-204.	1.9	3
97	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 783-795.	1.1	3
98	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	0.8	3
99	Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	0.9	3
100	Outcome and clinical biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. <i>Annals of Oncology</i> , 2012, 23, 2884-2890.	0.6	2
101	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
102	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 309.	0.6	1
103	The role of maintenance strategies in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 152-156.	0.3	1
104	Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 805-814.	1.1	1
105	Management of breast cancer patients during the peak of the COVID 19 pandemic. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2694-2695.	0.5	1
106	First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11547-e11547.	0.8	1
107	Role of breast surgery in T1-T3 breast cancer patients with synchronous bone metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1115-1115.	0.8	1
108	A meta-analysis of receptor status discordance between primary breast cancer and metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 546-546.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the "SOLE" trial.. Journal of Clinical Oncology, 2018, 36, 517-517.	0.8	1
110	Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTh)-naïve advanced melanoma (MM) patients (pts): A phase II study.. Journal of Clinical Oncology, 2010, 28, 8536-8536.	0.8	1
111	Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC).. Journal of Clinical Oncology, 2011, 29, 1056-1056.	0.8	1
112	Abstract PD8-04: Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway. , 2020, , .		1
113	Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 577-591.		0
114	Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial). Annals of Oncology, 2017, 28, v99.	0.6	0
115	155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Annals of Oncology, 2020, 31, S72.	0.6	0
116	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.. Journal of Clinical Oncology, 2021, 39, 1059-1059.	0.8	0
117	Expert Discussion: Predictive Markers. Breast Care, 2021, 16, 1-6.	0.8	0
118	Pegylated liposomal doxorubicin (PLA) at a metronomic schedule for patients with advanced breast cancer (ABC). Journal of Clinical Oncology, 2006, 24, 10571-10571.	0.8	0
119	Waiting room related symptoms: Patients'™ experiences in an outpatient clinic of a cancer center. Journal of Clinical Oncology, 2008, 26, 20614-20614.	0.8	0
120	Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. Journal of Clinical Oncology, 2009, 27, e14572-e14572.	0.8	0
121	A prognostic model for predicting breast cancer (BC)-related survival in operable triple-negative (TN) patients (pts).. Journal of Clinical Oncology, 2012, 30, 1049-1049.	0.8	0
122	ALGA: A cancer patient profiling tool to improve physician-patient communication"An analysis in breast cancer patients.. Journal of Clinical Oncology, 2013, 31, 9582-9582.	0.8	0
123	Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99. , 2015, , .		0
124	Abstract P2-14-18: Caelyx® as adjuvant treatment in early stage luminal B breast cancer: A feasibility phase II trial. , 2020, , .		0